POPULATION ANALYSIS OF THE PHARMACOKINETIC VARIABILITY OF HIGH-DOSE METOCLOPRAMIDE IN CANCER-PATIENTS

被引：16

作者：

GREVEL, J

WHITING, B

KELMAN, AW

TAYLOR, WB

BATEMAN, DN

机构：

[1] UNIV GLASGOW,STOBHILL GEN HOSP,DEPT MAT MED,GLASGOW G21 3UW,SCOTLAND

[2] W SCOTLAND HLTH BOARDS,DEPT CLIN PHYS & BIOENGN,GLASGOW G4 9LF,SCOTLAND

[3] UNIV NEWCASTLE UPON TYNE,WOLFSON UNIT CLIN PHARMACOL,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND

来源：

CLINICAL PHARMACOKINETICS | 1988年 / 14卷 / 01期

关键词：

D O I：

10.2165/00003088-198814010-00004

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：52 / 63

页数：12

共 28 条

[11] METOCLOPRAMIDE - AN UPDATED REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND CLINICAL USE [J].

HARRINGTON, RA ;

HAMILTON, CW ;

BROGDEN, RN ;

LINKEWICH, JA ;

ROMANKIEWICZ, JA ;

HEEL, RC .

DRUGS, 1983, 25 (05) :451-494

[12]

KRIS MG, 1983, NEW ENGL J MED, V309, P433

[13] METOCLOPRAMIDE KINETICS IN PATIENTS WITH IMPAIRED RENAL-FUNCTION AND CLEARANCE BY HEMODIALYSIS [J].

LEHMANN, CR ;

HEIRONIMUS, JD ;

COLLINS, CB ;

ONEIL, TJ ;

PIERSON, WP ;

CROWE, JT ;

MELIKIAN, AP ;

WRIGHT, GJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (03) :284-289

[14] POPULATION PHARMACOKINETICS OF ALFENTANIL - THE AVERAGE DOSE-PLASMA CONCENTRATION RELATIONSHIP AND INTERINDIVIDUAL VARIABILITY IN PATIENTS [J].

MAITRE, PO ;

VOZEH, S ;

HEYKANTS, J ;

THOMSON, DA ;

STANSKI, DR .

ANESTHESIOLOGY, 1987, 66 (01) :3-12

[15] PHARMACOKINETICS OF HIGH-DOSE METOCLOPRAMIDE IN CANCER-PATIENTS [J].

MCGOVERN, EM ;

GREVEL, J ;

BRYSON, SM .

CLINICAL PHARMACOKINETICS, 1986, 11 (06) :415-424

[16] OPTIMIZING METOCLOPRAMIDE CONTROL OF CISPLATIN-INDUCED EMESIS [J].

MEYER, BR ;

LEWIN, M ;

DRAYER, DE ;

PASMANTIER, M ;

LONSKI, L ;

REIDENBERG, MM .

ANNALS OF INTERNAL MEDICINE, 1984, 100 (03) :393-395

[17] POPULATION PHARMACOKINETICS OF RACEMIC WARFARIN IN ADULT PATIENTS [J].

MUNGALL, DR ;

LUDDEN, TM ;

MARSHALL, J ;

HAWKINS, DW ;

TALBERT, RL ;

CRAWFORD, MH .

JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1985, 13 (03) :213-227

[18] IMPROVED BENEFIT RISK RATIO OF HIGHER-DOSE METOCLOPRAMIDE THERAPY DURING CISPLATIN-INDUCED EMESIS [J].

SALLER, R ;

HELLENBRECHT, D ;

HELLSTERN, A ;

HESS, H .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 29 (03) :311-312

[19] EVALUATION OF METHODS FOR ESTIMATING POPULATION PHARMACOKINETIC PARAMETERS .3. MONOEXPONENTIAL MODEL - ROUTINE CLINICAL PHARMACOKINETIC DATA [J].

SHEINER, LB ;

BEAL, SL .

JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1983, 11 (03) :303-319

[20] EVALUATION OF METHODS FOR ESTIMATING POPULATION PHARMACOKINETIC PARAMETERS .2. BIEXPONENTIAL MODEL AND EXPERIMENTAL PHARMACOKINETIC DATA [J].

SHEINER, LB ;

BEAL, SL .

JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1981, 9 (05) :635-651

← 1 2 3 →